Related Experiment Video
Updated: Jul 31, 2025

The Use of Mixed Reality in Custom-Made Revision Hip Arthroplasty: A First Case Report
Published on: August 4, 2022
Current and emerging therapies for Achondroplasia: The dawn of precision medicine
Etienne Dardenne1, Noboru Ishiyama2, Tai-An Lin1
1Black Diamond Therapeutics, New York, NY, USA.
Abstract:
Achondroplasia is a rare disease affecting bone growth and is caused by a missense mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. In the past few years, there were multiple experimental drugs entering into clinical trials for treating achondroplasia including vosoritide, the first precision medicine approved for this indication. This perspective presents the mechanism of action, benefit, and potential mechanistic limitation of the drugs currently being evaluated in clinical trials for achondroplasia. This article also discusses the potential impact of those drugs not only in increasing the growth of individuals living with achondroplasia but also in improving their quality of life.
More Related Videos
09:57Development and Evaluation of 3D-Printed Cardiovascular Phantoms for Interventional Planning and Training
Published on: January 18, 2021
11:22Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Gene Therapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Microorganisms in Medicine and Therapeutics
iPS Cell Differentiation